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Purpose: To study the concentration of vascular endothelial growth factor (VEGF) in the aqueous humor before 
and after intracameral injection of bevacizumab in eyes with neovascular glaucoma, and to detect the duration of 
an anti-VEGF effect of bevacizumab in the anterior chamber.
Methods: In this prospective interventional case series, 1.25 mg of bevacizumab was injected into the anterior chamber 
of five eyes in five neovascular glaucoma patients. Aqueous humor samples were obtained just before intracameral 
injection of bevacizumab and two weeks after injection. The concentrations of VEGF in the aqueous humor were 
measured using ELISA. To investigate corneal endothelial damage after intrecameral bevacizumab injection, specular 
microscopy was performed before injection and two weeks after injection. Slit lamp photo and iris fluorescent an-
giography was performed to determine the regression of iris neovascularization.
Results:  After injection, substantial regression of neovascularization or fluorescein leakage was seen in all treated 
eyes. The VEGF concentrations in the aqueous humor in eyes with NVG were 1181.8±1248.3 pg/mL before intra-
cameral injection of bevacizumab. Two weeks after injection, the VEGF concentrations decreased to 33.2±12.2 pg/ 
mL (p=0.04, Wilcoxon signed rank test). There were no significant changes in IOP or corneal endothelial cells.
Conclusions: Intracameral bevacizumab injection can remarkably reduce iris neovascularization in neovascular 
glaucoma patients. VEGF levels were significantly decreased two weeks after injection and corneal toxicity was not 
observed during short term follow-up.
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Vascular endothelial growth factor (VEGF) is akey regulator 
of pathological ocular neovascularization and is elevated in the 
aqueous humor of patients with neovascular glaucoma (NVG) 
secondary to proliferative vasculopathies such as proliferative 
diabetic retinopathy (PDR) and central retinal vein occlusion 
(CRVO).
1,2 
In addition to VEGF, other substances that may have a role 
in the development of NVG include basic fibroblast growth 
factor, platelet-derived growth factor, and insulin-like growth 
factor-I.
3-7
Preparations that inhibit the effects of  VEGF have recently 
become available.
Among these, bevacizumab (Avastin; Genentech, San Fran-
cisco, CA, USA), a recombinant humanized monoclonal im-
munoglobulin antibody, is an anti-human VEGF agent approved 
as an adjunct treatment for colorectal cancer.
8 Its off-label in-
travitreal use has shown promise for treatment of neovascular 
age-related macular degeneration, proliferative diabetic reti-
nopathy and macular edema secondary to central retinal vein 
occlusion.
Intracameral injection of bevacizumab is currently in clini-
cal trials, and some studies have shown that intracameral as 
well as intravitreal injection of bevacizumab result in a remark-
able reduction in aqueous humor levels of  VEGF and iris neo-
vasculization.
2 But there is little information about the proper 
timing for subsequent injections of intracameral bevacizuamb, 
or about the short term side effects of intracameral bevacizumab 
to the cornea. In this study, we injected bevacizumab into the 
anterior chambers of  NVG patients, whose neovascularization 
is secondary to PDR or CRVO, and compared the levels of 
VEGF in the aqueous humor before injection and two weeks 
after injection. We also investigated the toxic effectsof beva-
cizumab on corneal endothelial cells using specular microscopy.
Materials and Methods
After obtaining informed consent, we collected operating TH Lim, et al. INTRACAMERAL BEVACIZUMAB INJECTION
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Fig. 1. Vascular endothelial growth factor (VEGF) in the aqueous 
humor of eyes with neovascular glaucoma. VEGF levels are shown 
before intracameral bevacizumab injection (pre-bevacizumab), two 
weeks after injection (post-bevacizumab) and for the control group.
Table 1. Changes in cell density and morphology of corneal endothelial cells after intracameral bevacizumab injection
Corneal endothelial cell density
(number/mm
2)
Coefficient of variation
*
(%, (range))
Hexagonality
†
(%, (range))
pre-bevacizumab 2246±552 37.8 (34-49) 52.8 (31-58)
post-bevacizumab 2254±589 38.2 (34-52) 49.2 (30-62)
* Coefficient of variation=standard deviation of area of endothelial cell/average area of endothelial cell×100; 
† Hexagonality=percentage of 
hexagonal cells no statistically significant difference by Wilcoxon signed rank test  p>0.05.
room samples of aqueous humor from five human subjects 
(age range, 43-87 years; mean, 64.2+13.1). Clinically, three of 
the patients had a proliferative diabetic retinopathy and two had 
a CRVO. All patients suffered from neovascular glaucoma due 
to retinal ischemia. Complete sessions of laser photocoagulation 
were performed on the ischemic retinas of all patients and be-
vacizumab was injected intravitreally on three of five eyes during 
the outpatient follow up period, but no therapeutic intervention 
on the retina was done within six months before and two weeks 
after first intracameral bevacizumab injection. On gonioscopic 
examination, three patients had peripheral anterior synechia of 
about 120 degrees and angles were partially opened. Another 
two patients had peripheral anterior synechia around 360 degrees 
with closed angle. The mean intraocular pressure (IOP) was 
29.2±10 mmHg (16 to 44 mmHg). All of the patients had used 
two to three anti-glaucoma drugs to lower intraocular pressure 
and maintained use of these medications after intracameral 
bevacizumab injection.
Aqueous humor was also sampled before cataract surgery 
from eight eyes in eight patients (age range, 70-86 years mean, 
67.4+10.8) with cataracts who did not have diabetes mellitus 
or other ocular diseases.
After the eye had been prepared in a standard fashion using 
5% povidone/iodine and topical antibiotics, we obtained 0.1 to 
0.2 ml of undiluted aqueous humor by limbal paracentesis using 
a 30-gauge needle attached to a microsyringe. We aspirated the 
aqueous humor within two to five seconds from the central 
pupillary area without touching the iris, lens, or corneal endo-
thelium. The samples were placed immediately in liquid nitro-
gen and stored at -70℃ until analyzed. A total of 0.05 mL (1.25 
mg) of undiluted bevacizumab was injected intracamerally 
through the limbus. After the injection, IOP and retinal artery 
perfusion were assessed, and patients were instructed to ad-
minister topical antibiotics (levofloxacin) for three days. 
Aqueous sampling and bevacizumab injection were repeated 
after two weeks. Patients with established NVG were treated 
with medical and/or surgical therapy as needed. Ophthalmic 
evaluation included complete ophthalmic examination inclu-
ding degree of iris neovascularization and IOP, iris angiogra-
phy, specular microscopy and slit lamp photography. The pa-
tients’ records were reviewed to record patient demographics 
and clinical data. 
Total VEGF concentrations were determined by ELISA (Cat. 
DVE00, R&D Systems, Minneapolis, MN USA) according to 
the manufacturer’s instructions. The intensity of color develop-
ed was measured using an ELISA reader (MQX-200, Bio- 
TEK Instruments, Inc.) at 450 nm optical density (OD) with 
correction at 570 nm. 
Before injection and two weeks after injection, corneal en-
dothelial density, coefficient of variation and hexagonality were 
measured with specular microscopy, and intraocular pressure 
was measured with a Goldmann applanation tonometer.
Results
The mean VEGF concentration in the aqueous humor in 
eyes with NVG was 1181.8±1248.3 pg/mL (46.0 to 2745.7 
pg/mL) before intracameral injection of bevacizumab and 
that of the control group was 20.7±12.4 pg/mL. Two weeks 
after injection, the VEGF concentrations in the test group had 
decreased to 33.2±12.2 pg/mL(14.0 to 43.7 pg/mL) (p-=0.04) 
(Fig. 1). IOP was 29.2±10.1 mmHg before bevacizumab in-
jection, 30.8±8.4 mmHg right after injection and dropped to 
24.0±7.3 mmHg 2 weeks after injection, but the differences in 
these levels were not significant. 
On specular microscopy examination, corneal endothelial 
density, coefficient of variation and hexagonality were 2246 
±552, 37.8±6.3, 52.8±12.1 respectively before bevacizumab 
injection and 2254±589, 38.2±8.1, 49.2±12.1 respectively two 
weeks after injection (p>0.05) (Table 1).
High-quality iris fluorescein angiographs were obtained be-
fore and after intracameral bevacizumab injection in five eyes. Korean J Ophthalmol Vol.23, No.3, 2009
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Fig. 2. (A) A NVG patient showing iris neovascularization before bevacizumab injection. (B) Two weeks after intracameral bevacizumab in-
jection, neovascularization had completely regressed.
AB
Fig. 3. (A) Iris fluorescein angiogram shows marked dye leakage from rubeotic vessels before intracameral vevacizumab injection. (B) Two 
weeks after intracameral bevacizumab injection, the leakage from iris neovascularization was remarkably decreased.
Two weeks after injection of bevacizumab, substantial regre-
ssion of neovascularization or fluorescein leakage was seen in 
all eyes (Fig. 2, 3).
No complications developed after injection of bevacizumab, 
such as uveitis, endophthalmitis, effects of ocular toxic effects, 
or other obvious systemic adverse events. Blood pressure was 
monitored before initial injection and at each follow-up, and 
no significant elevations were observed over the course of the 
study.
Discussion
Iris neovascularization with secondary angle-closure glau-
coma is a serious sequela of a number of disease processes affec-
ting the eye. Clinical studies indicate that diabetic retinopathy, 
retinal venous obstruction, and sickle cell disease are the leading 
etiologic factors for the development of NVG.
1, 2, 9 It is now 
evident that several mediators are involved in the process of 
neovascularization, the most important and well studied of 
which is the VEGF-A.
10-12
Ramesh et al. found that patients with NVG had significantly 
increased levels of VEGF in the aqueous humor, 40- and 113- 
fold higher than in patients with POAG or cataract, respectively, 
and implicated VEGF as an important factor in the pathogenesis 
of intraocular neovascularization.
7 
In animal studies, Tolentino et al. concluded that intravitreal TH Lim, et al. INTRACAMERAL BEVACIZUMAB INJECTION
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injections of recombinant human VEGF165 in amounts com-
parable to those measured in eyes with active neovascularization 
are sufficient to produce noninflammatory iris neovasculari-
zation in nonhuman primates and that prolonged exposure to 
VEGF165 can produce neovascular glaucoma.
13 
Regarding the pivotal role of VEGF-A in ocular neovas-
cularization, inhibition of this mediator appears to have a strong 
biologic basis for treatment of NVG.
10-12
Shahin et al. reported two cases with neovascular glaucoma 
secondary to ischemic entral retinal vein occlusion who received 
treatment with intravitreal bevacizumab (Avastin), which is a 
nonselective antibody against VEGF-A. Both patients demonst-
rated dramatic short-term response in terms of intraocular pre-
ssure reduction and regression of neovascularization.
10
In another case report, Milko et al injected bevacizumab 
intravitreally to six consecutive patients with NVG and intra-
vitreal bevacizumab resulted in a marked regression of anterior 
segment neovascularization and relief of symptoms within 48 
hours. IOP also decreased substantially in three eyes without 
further treatment.
14 
In a case of intravitreal bevacizumab injection in a patient 
with early stage neovascular glaucoma without peripheral an-
terior synechia, the visual acuity, IOP, regression of the iris and 
the angle of neovascularization were measured up to the 29 
weeks after injection. Regression of the iris and angle of neo-
vascularization were confirmed from the second week after 
injection.
15
In a study of intracameral bevacizumab injection, 16 eyes 
of 15 patients with iris neovascularization associated with or 
without neovascular glaucoma secondary to proliferative retinal 
vasculopathies received intracameral bevacizumab (1.25 mg) 
and all patients had complete remission of the neovasculari-
zation within three weeks after the injection. Intraocular pre-
ssure was controlled with maximum medical therapy in eight 
of nine eyes reducing the need for glaucoma surgery.
2
In our study, we injected bevacizumab in the anterior chamber 
of 5 NVG subjects. Two weeks after injection, in all the eyes, 
the leakage from iris neovascularization was decreased and en-
gorged vesselswere regressed on an iris fluorescein angiogram. 
It was a similar result to that of other studies, but concerning 
intraocular pressure, there was no significant IOP lowering 
effect two weeks after injection. 
Osamu et al. in their study of intravitreal bevacizumab in-
jection on NVG patients, found that the VEGF concentration in 
the aqueous humor averaged 326±125 pg/mL before intravitreal 
injection of bevacizumab and decreased to less than 31 pg/mL 
in all eyes one week after injection, about a 10 fold decrease.
16
In our study, VEGF levels were remarkably lowered to 33.2 
pg/mL after intracameral bevacizumab injection, at least a 30 
fold decrease, much higher than that seen after intravitreal in-
jection. Reduced neovascularization may lead to a decrease in 
release of inflammatory cytokines from theiris and retinal ve-
ssels of neovascular glaucoma patients, and reduce the occurrence 
of peripheral anterior synechia. 
Considering that our study measured VEGF levels two weeks 
after injection, the decrease in intracameral VEGF levels that 
we observed suggest that subsequent intracameral injections 
may be delayed for more than two weeks and still constitute 
effective treatment. Comparing these results to the effects of 
intravitreal injection, the amount of bevacizumab necessary 
could be reduced for intracameral injections.
In a prospective case series, Chiang et al. injected 2.5 mg of 
bevacizumab intravitreally into 50 eyes of 50 patients. Corneal 
endothelial cell densities of treated and untreated eyes before 
injection and at three and six months after injection were not 
significantly different. They concluded that intravitreal injection 
of 2.5 mg bevacizumab seemed to have no harmful effects on 
the corneal endothelium.
17
Also, in cultured human corneal cells, there were no cytotoxic 
effects of bevacizumab on corneal keratinocytes, corneal fib-
roblasts, and corneal endothelial cells when used at concentra-
tions of 5.0 mg/mL or lower. Bevacizumab-treated cells showed 
no signs of cellular damage compared with the control.
18
In our study, two weeks after intracameral bevacizumab 
injection, there was no significant progression in polymegathism 
and pleomorphism of corneal endothelial cells, thus bevaci-
zumab has no harmful effects on corneal endothelial cells. But 
a longer follow-up is needed to determine the safety of intra-
cameral bevacizumab.
In conclusion, intracameral bevacizumab injection can re-
duce iris neovascularization in NVG patients. VEGF levels were 
significantly decreased two weeks after injection and corneal 
toxicity did not occur during the short term follow-up period.
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